Review article: the gut microbiome in inflammatory bowel disease—avenues for microbial management
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Summary: Background: The concept of an altered collective gut microbiota rather than identification of a single culprit is possibly the most significant development in inflammatory bowel disease research. We have entered the “omics” era, which now allows us to undertake large‐scale/high‐throughput microbiota analysis which may well define how we approach diagnosis and treatment of inflammatory bowel disease (IBD) in the future, with a strong steer towards personalised therapeutics. Aim: To assess current epidemiological, experimental and clinical evidence of the current status of knowledge relating to the gut microbiome, and its role in IBD, with emphasis on reviewing the evidence relating to microbial therapeutics and future microbiome modulating therapeutics. Methods: A Medline search including items ‘intestinal microbiota/microbiome’, ‘inflammatory bowel disease’, ‘ulcerative colitis’, ‘Crohn's disease’, ‘faecal microbial transplantation’, ‘dietary manipulation’ was performed. Results: Disease remission and relapse are associated with microbial changes in both mucosal and luminal samples. In particular, a loss of species richness in Crohn's disease has been widely observed. Existing therapeutic approaches broadly fall into 3 categories, namely: accession, reduction or indirect modulation of the microbiome. In terms of microbial therapeutics, faecal microbial transplantation appears to hold the most promise; however, differences in study design/methodology mean it is currently challenging to elegantly translate results into clinical practice. Conclusions: Existing approaches to modulate the gut microbiome are relatively unrefined. Looking forward, the future of microbiome‐modulating therapeutics looks bright with several novel strategies/technologies on the horizon. Taken collectively, it is clear that ignoring the microbiome in IBD is not an option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413
Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“difficile infection.(126) The effects were dra-”
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872 · cited 1×
“tory immune responses by activating regulatory T (Treg) cells 156 as well as data that show that inoculation of clostridia during early life reared mice resistant to colitis.(157) Cluster XIVa contains highly oxygen-sensitive organisms of clinical importance in UC pathogenesis,”
BackgroundDysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
Self-citationReduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548 · cited 2×
“infection is suspected.(77) There is no evidence to support a routine”
BackgroundMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499 · cited 1×
“pared from a healthy donor or drinking water (placebo) via retention enema.(136) Patients who received FMT met the robust primary end-”
Methodde Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
Ott, S. J., Musfeldt, M., Wenderoth, D. F., Hampe, J., Brant, O., Fölsch, U. R., Timmis, K. N., & Schreiber, S. (2004) · Gut · doi:10.1136/gut.2003.025403 · Cited by 1,311
Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease
Norman, J. M., Handley, S. A., Baldridge, M. T., Droit, L., Liu, C. Y., Keller, B. C., Kambal, A., Monaco, C. L., Zhao, G., Fleshner, P., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.002 · Cited by 1,285 · cited 2×
“However, the inverse relationship between the bacteria and the virome could not be reliably replicated in the validation USA cohorts in the study.(47) Subtle distinctions were noted between patients with CD and ulcerative colitis, wherein in the former group”
BackgroundMethodKruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276 · cited 1×
“receive either FMT or placebo (isotonic saline with added brown food colourant and odorant) administered once by colonoscopy, followed by 39 self-administered enemas over 8 weeks.(137) The faecal microbiota administered to patients was prepared from a mix of”
MethodConsensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083 · cited 2×
“The focus has therefore fallen on enteral nutrition in CD, with recognition that exclusive liquid diets for periods of 6- 8 weeks are highly effective in inducing remission in ~80% of paedi- atric patients with active luminal CD, leading to exclusive enteral nutrition being promoted as first-line therapy in paediatric…”
BackgroundInteractions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis
Iliev, I. D., Funari, V. A., Taylor, K. D., Nguyen, Q., Reyes, C. N., Strom, S. P., Brown, J., Becker, C. A., Fleshner, P. R., Dubinsky, M., et al. (2012) · Science · doi:10.1126/science.1221789 · Cited by 1,073
Willing, B. P., Dicksved, J., Halfvarson, J., Andersson, A. F., Lucio, M., Zheng, Z., Järnerot, G., Tysk, C., Jansson, J. K., & Engstrand, L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.049 · Cited by 1,032
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921 · cited 1×
“colitis to undergo 2 FMTs via nasoduodenal tube, containing faeces from either a healthy donor or patients own stool.(142) The authors reported that there was no statistically significant difference in clini-”
MethodKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Swidsinski, A., Weber, J., Loening-Baucke, V., Hale, L. P., & Lochs, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3380-3389.2005 · Cited by 894 · cited 1×
“cies has also been documented with higher proportions of Bacteroides fragilis being seen in IBD patients.(20) In CD, changes in Firmicutes have particularly documented changes in Faecalibacterium prausnitzii.”
BackgroundArchaea and fungi of the human gut microbiome: correlations with diet and bacterial residents
Hoffmann, C., Dollive, S., Grunberg, S., Chen, J., Li, H., Wu, G. D., Lewis, J. D., & Bushman, F. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066019 · Cited by 808
Ott, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695 · cited 1×
“difficile infection.(130) The success of FMT as a treatment for recurrent C.”
BackgroundFine-mapping inflammatory bowel disease loci to single-variant resolution
International Inflammatory Bowel Disease Genetics Consortium, Huang, H., Fang, M., Jostins, L., Umićević Mirkov, M., Boucher, G., Anderson, C. A., Andersen, V., Cleynen, I., Cortes, A., et al. (2017) · Nature · doi:10.1038/nature22969 · Cited by 611
Chassaing, B., Van de Wiele, T., De Bodt, J., Marzorati, M., & Gewirtz, A. T. (2017) · Gut · doi:10.1136/gutjnl-2016-313099 · Cited by 590 · cited 1×
“of the microbial substrate hypothesis, potentially opening avenues for increased pathogenic potential within the host microbiota.(178)”
BackgroundSood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513 · cited 1×
“jects with mild-to-moderately active ulcerative colitis, either combined with standard treatment(99) or alone.(100) In a meta-analysis,”
BackgroundMetagenomic approaches for defining the pathogenesis of inflammatory bowel diseases
Peterson, D. A., Frank, D. N., Pace, N. R., & Gordon, J. I. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.001 · Cited by 503
Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu135 · Cited by 467 · cited 1×
“frequent dosing and would simplify the design of placebo-controlled trials, though dose limitation may become a factor.(150)”
BackgroundLopez-Siles, M., Khan, T. M., Duncan, S. H., Harmsen, H. J. M., Garcia-Gil, L. J., & Flint, H. J. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.06858-11 · Cited by 433 · cited 2×
“prausnitzii was also seen in CD patients, in marked contrast to numerous other reports.(26,28,34-37) A larger study comprising of 447 MCILROY ET AL.”
BackgroundResultKato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397
Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn's Disease
Erickson, A. R., Cantarel, B. L., Lamendella, R., Darzi, Y., Mongodin, E. F., Pan, C., Shah, M., Halfvarson, J., Tysk, C., Henrissat, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049138 · Cited by 395
Shen, J., Zuo, Z.-X., & Mao, A.-P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000437495.30052.be · Cited by 364 · cited 1×
“74) after analysis of strain subgroups.(106) A further Cochrane review found that probiotics were ineffective in the maintenance of remission in ulcerative colitis,(107) although a meta-analysis of RCTs showed their efficacy in the prevention of pouchitis.”
BackgroundDecreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease
Fujimoto, T., Imaeda, H., Takahashi, K., Kasumi, E., Bamba, S., Fujiyama, Y., & Andoh, A. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12073 · Cited by 304
Treatment of ulcerative colitis by implantation of normal colonic flora
Bennet, J., & Brinkman, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91183-5 · Cited by 304
TAKAGI, S., UTSUNOMIYA, K., KURIYAMA, S., YOKOYAMA, H., TAKAHASHI, S., IWABUCHI, M., TAKAHASHI, H., TAKAHASHI, S., KINOUCHI, Y., HIWATASHI, N., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03120.x · Cited by 292 · cited 1×
“nutrition vs 64% on free diet, over nearly 12-month follow-up, after induction of remission with exclusive enteral nutrition in 92%.(172) Unsurprisingly, the message of larger volumes of enteral”
BackgroundKump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235
Borody, T. J., George, L., Andrews, P., Brandl, S., Noonan, S., Cole, P., Hyland, L., Morgan, A., Maysey, J., & Moore‐Jones, D. (1989) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb136704.x · Cited by 221
LEACH, S. T., MITCHELL, H. M., ENG, W. R., ZHANG, L., & DAY, A. S. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03796.x · Cited by 164
Luo, Y., de Lange, K. M., Jostins, L., Moutsianas, L., Randall, J., Kennedy, N. A., Lamb, C. A., McCarthy, S., Ahmad, T., Edwards, C., et al. (2017) · Nature Genetics · doi:10.1038/ng.3761 · Cited by 162
Vahabnezhad, E., Mochon, A. B., Wozniak, L. J., & Ziring, D. A. (2013) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318279abf0 · Cited by 156 · cited 1×
“Finally, probiotics have also been shown to cause sepsis in patients with ulcerative colitis.(109) This finding suggests that probiotics are not always free from side effects, especially in high-risk patients (such as”
BackgroundEnteral nutrition and microflora in pediatric Crohn's disease
Lionetti, P., Callegari, M. L., Ferrari, S., Cavicchi, M. C., Pozzi, E., de Martino, M., & Morelli, L. (2005) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/01486071050290s4s173 · Cited by 150 · cited 1×
“microbial study of exclusive enteral nutrition suggested either the low residue nature or potential prebiotic properties of the diet as potential modulators of the microbiome.(167) Recent data, however, demonstrate that the mechanism of action is paradoxical when compared to our understanding of CD pathogenesis.”
ResultMukhopadhya, I., Thomson, J. M., Hansen, R., Berry, S. H., El-Omar, E. M., & Hold, G. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021490 · Cited by 145
Self-citationEnteral nutrition for the maintenance of remission in Crohnʼs disease: a systematic review
Yamamoto, T., Nakahigashi, M., Umegae, S., & Matsumoto, K. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832c788c · Cited by 81
E. coli-mediated gut inflammation in genetically predisposed Crohn's disease patients
Barnich, N., Denizot, J., & Darfeuille-Michaud, A. (2013) · Pathologie Biologie · doi:10.1016/j.patbio.2010.01.004 · Cited by 34
Cited by
Clinical Application and Potential of Fecal Microbiota Transplantation
Ooijevaar, R. E., Terveer, E. M., Verspaget, H. W., Kuijper, E. J., & Keller, J. J. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-111717-122956 · Cited by 336
Burrello, C., Garavaglia, F., Cribiù, F. M., Ercoli, G., Lopez, G., Troisi, J., Colucci, A., Guglietta, S., Carloni, S., Guglielmetti, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07359-8 · Cited by 307
The promise of the gut microbiome as part of individualized treatment strategies
Schupack, D. A., Mars, R. A. T., Voelker, D. H., Abeykoon, J. P., & Kashyap, P. C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00499-1 · Cited by 217
Kedia, S., Virmani, S., K Vuyyuru, S., Kumar, P., Kante, B., Sahu, P., Kaushal, K., Farooqui, M., Singh, M., Verma, M., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327811 · Cited by 201
Klingberg, E., Magnusson, M. K., Strid, H., Deminger, A., Ståhl, A., Sundin, J., Simrén, M., Carlsten, H., Öhman, L., & Forsblad-d’Elia, H. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-2018-4 · Cited by 101
Metadata
- Authors
- McIlroy, J., Ianiro, G., Mukhopadhya, I., Hansen, R., & Hold, G. L.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-10-16
- Volume
- 47
- Issue
- 1
- Pages
- 26-42
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2765875974
- Cited by
- 176
- References
- 46
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.